PROK Valuation

ProKidney Corp

Add to Watchlist

Advanced Chart

2.590

+0.025(0.975%)1D

Overview
Forecast
Valuation
Earnings

PROK Relative Valuation

PROK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PROK is overvalued; if below, it's undervalued.

Historical Valuation

ProKidney Corp (PROK) is now in the Fair zone, suggesting that its current forward PS ratio of 2479.76 is considered Fairly compared with the five-year average of -5.49. The fair price of ProKidney Corp (PROK) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：2.59

Fair

-4.51

Trailing

Forward

-7.78

EV/EBITDA

ProKidney Corp. (PROK) has a current EV/EBITDA of -7.78. The 5-year average EV/EBITDA is -6.49. The thresholds are as follows: Strongly Undervalued below -14.38, Undervalued between -14.38 and -10.43, Fairly Valued between -2.54 and -10.43, Overvalued between -2.54 and 1.41, and Strongly Overvalued above 1.41. The current Forward EV/EBITDA of -7.78 falls within the Historic Trend Line -Fairly Valued range.

-7.29

EV/EBIT

ProKidney Corp. (PROK) has a current EV/EBIT of -7.29. The 5-year average EV/EBIT is -6.21. The thresholds are as follows: Strongly Undervalued below -13.89, Undervalued between -13.89 and -10.05, Fairly Valued between -2.37 and -10.05, Overvalued between -2.37 and 1.48, and Strongly Overvalued above 1.48. The current Forward EV/EBIT of -7.29 falls within the Historic Trend Line -Fairly Valued range.

2479.76

ProKidney Corp. (PROK) has a current PS of 2479.76. The 5-year average PS is 106.48. The thresholds are as follows: Strongly Undervalued below -925.84, Undervalued between -925.84 and -409.68, Fairly Valued between 622.64 and -409.68, Overvalued between 622.64 and 1138.79, and Strongly Overvalued above 1138.79. The current Forward PS of 2479.76 falls within the Strongly Overvalued range.

-6.25

P/OCF

ProKidney Corp. (PROK) has a current P/OCF of -6.25. The 5-year average P/OCF is -2.85. The thresholds are as follows: Strongly Undervalued below -8.02, Undervalued between -8.02 and -5.43, Fairly Valued between -0.26 and -5.43, Overvalued between -0.26 and 2.33, and Strongly Overvalued above 2.33. The current Forward P/OCF of -6.25 falls within the Undervalued range.

-4.79

P/FCF

ProKidney Corp. (PROK) has a current P/FCF of -4.79. The 5-year average P/FCF is -1.96. The thresholds are as follows: Strongly Undervalued below -5.48, Undervalued between -5.48 and -3.72, Fairly Valued between -0.21 and -3.72, Overvalued between -0.21 and 1.55, and Strongly Overvalued above 1.55. The current Forward P/FCF of -4.79 falls within the Undervalued range.

ProKidney Corp (PROK) has a current Price-to-Book (P/B) ratio of -0.33. Compared to its 3-year average P/B ratio of 13.69 , the current P/B ratio is approximately -102.43% higher. Relative to its 5-year average P/B ratio of 45.51, the current P/B ratio is about -100.73% higher. ProKidney Corp (PROK) has a Forward Free Cash Flow (FCF) yield of approximately -44.12%. Compared to its 3-year average FCF yield of -60.82%, the current FCF yield is approximately -27.46% lower. Relative to its 5-year average FCF yield of -48.69% , the current FCF yield is about -9.38% lower.

-0.33

P/B

Median3y

13.69

Median5y

45.51

-44.12

FCF Yield

Median3y

-60.82

Median5y

-48.69

Competitors Valuation Multiple

The average P/S ratio for PROK's competitors is 418.75, providing a benchmark for relative valuation. ProKidney Corp Corp (PROK) exhibits a P/S ratio of 2479.76, which is 492.18% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Nurix Therapeutics Inc

Syndax Pharmaceuticals Inc

Xeris Biopharma Holdings Inc

Performance Decomposition

Market capitalization of PROK increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of PROK in the past 1 year is driven by Unknown.